The current role of systemic chemotherapy in the primary treatment of head and neck cancer

• Interpreting studies including ICT in HNSCC is complicated by several protocols, treatment settings and different endpoints.
• ICT has a role in selected HNSCC patients with high risk for distant metastasis.
• ICT is beneficial for selected patients, who can conduct the complex and toxic treatment schedule.

The treatment of patients with locoregionally advanced squamous cell carcinoma of the head and neck (HNSCC) is still evolving into the perfect combination of the different multidisciplinary approaches. Induction chemotherapy (ICT) prior to planned definitive local therapy is widely used in this patient population for over 30 years but it is still unclear how to incorporate ICT into multimodality treatment the best. It appears to have a role in selected clinical situations especially for those patients with high risk for distant metastasis. However, since ICT protocols in different studies varies a lot, a comparative and consistent statement of benefits is difficult.We show the recent developments including randomized trials comparing radiochemotherapy (RCT) and ICT followed by definitive RCT here. This review summarizes how ICT has developed over the years, provides critical remarks of recent developments, and discusses how clinical trials including ICT should be conducted in the future.